Paul Corn
Overview
Explore the profile of Paul Corn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassanzadeh C, Mohamad O, Bruno T, Wang L, Kudchakar R, Bathala T, et al.
Brachytherapy
. 2025 Jan;
24(2):231-237.
PMID: 39755443
Background: To determine outcomes of MRI-assisted radiosurgery (MARS) for salvage brachytherapy using the radioisotope Pd after various upfront treatments including surgery, external beam radiotherapy, and brachytherapy. Methods: We retrospectively reviewed...
2.
Schmidt M, Naghdloo A, Prabakar R, Kamal M, Cadaneanu R, Garraway I, et al.
Oncogene
. 2024 Nov;
44(7):439-449.
PMID: 39578659
Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues,...
3.
Hicks J, Schmidt M, Nahgdloo A, Prabakar R, Kamal M, Cadaneanu R, et al.
Res Sq
. 2024 Nov;
PMID: 39483900
Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues,...
4.
Schmidt M, Naghdloo A, Prabakar R, Kamal M, Cadaneanu R, Garraway I, et al.
bioRxiv
. 2024 Sep;
PMID: 39229204
Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues,...
5.
Sosa A, Rooney M, Thames H, Sanders J, Swanson D, Choi S, et al.
Clin Transl Radiat Oncol
. 2024 Aug;
48:100822.
PMID: 39188999
Background: Proton therapy (PT) has unique biologic properties with excellent clinical outcomes for the management of localized prostate cancer. Here, we aim to characterize the toxicity of PT for patients...
6.
Matin S, Adibi M, Shah A, Alhalabi O, Corn P, Guo C, et al.
J Urol
. 2024 Apr;
211(6):784-793.
PMID: 38573872
Purpose: We initiated a biomarker-informed preoperative study of infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet...
7.
Viscuse P, Slack-Tidwell R, Zhang M, Rohra P, Zhu K, San Lucas F, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136389
(AVPCs) are a subset of metastatic castrate-resistant prostate cancers (mCRPCs) characterized by defects in ≥ two of three of , , and (AVPCm), a profile linked to lineage plasticity, androgen...
8.
Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, et al.
Eur J Cancer
. 2021 Sep;
157:259-267.
PMID: 34536949
Background: Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naïve prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT...
9.
Chai S, Matsumoto N, Storgard R, Peng C, Aparicio A, Ormseth B, et al.
Mol Cancer Res
. 2021 Aug;
19(12):2036-2045.
PMID: 34462330
Metastatic castration-resistant prostate cancer (mCRPC) includes a subset of patients with particularly unfavorable prognosis characterized by combined defects in at least two of three tumor suppressor genes: , , and...
10.
Vardaki I, Corn P, Gentile E, Song J, Madan N, Hoang A, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3253-3264.
PMID: 33753455
Purpose: Radium-223 prolongs survival in a fraction of men with bone metastatic prostate cancer (PCa). However, there are no markers for monitoring response and resistance to Radium-223 treatment. Exosomes are...